A recent study suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a leading medical journal points out that while obese people frequently drop a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications must be informed of the danger of fast rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment weight within about 18 months.
Comparing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Scientists emphasize that people who lose weight through dieting usually experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists suggest the mechanism of the jabs accounts for the accelerated regain.
GLP-1 drugs copy a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is unsuppressed, making overeating far more likely."
An Ongoing Issue?
Medical guidelines advise the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, considering the high risk of weight regain, the treatment is often life-long.
This view is echoed by pharmaceutical companies, who say that the results "underscore the chronic nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have discontinued the jabs explain a powerful return of cravings.
"It was like something flipping and you're instantly starving," described a patient.
This difficulty is exacerbated if patients have not adopted permanent lifestyle or habit changes during treatment.
Significant Use
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on ongoing behavioural management.
